Twinbeech Capital LP Acquires Shares of 164,112 Arvinas, Inc. (NASDAQ:ARVN)

Twinbeech Capital LP acquired a new stake in Arvinas, Inc. (NASDAQ:ARVN - Free Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 164,112 shares of the company's stock, valued at approximately $3,146,000. Twinbeech Capital LP owned approximately 0.24% of Arvinas at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. KBC Group NV lifted its position in Arvinas by 77.0% during the 4th quarter. KBC Group NV now owns 2,885 shares of the company's stock worth $55,000 after buying an additional 1,255 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new position in Arvinas in the 4th quarter valued at about $171,000. Tema Etfs LLC bought a new stake in Arvinas in the 4th quarter valued at about $227,000. Teacher Retirement System of Texas boosted its holdings in Arvinas by 19.0% in the 4th quarter. Teacher Retirement System of Texas now owns 14,295 shares of the company's stock valued at $274,000 after purchasing an additional 2,280 shares during the period. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in Arvinas by 10.4% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 14,570 shares of the company's stock valued at $279,000 after purchasing an additional 1,367 shares during the period. 95.19% of the stock is owned by institutional investors.

Insider Activity at Arvinas

In other news, CEO John G. Houston sold 31,338 shares of the firm's stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $16.72, for a total transaction of $523,971.36. Following the sale, the chief executive officer now owns 1,157,480 shares of the company's stock, valued at $19,353,065.60. This trade represents a 2.64% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Noah Berkowitz sold 8,658 shares of the firm's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $8.59, for a total value of $74,372.22. Following the completion of the transaction, the insider now owns 110,023 shares in the company, valued at $945,097.57. The trade was a 7.30% decrease in their position. The disclosure for this sale can be found here. Insiders sold 50,230 shares of company stock worth $769,402 over the last three months. 4.73% of the stock is owned by corporate insiders.

Arvinas Stock Up 0.6%

Shares of NASDAQ ARVN traded up $0.04 during trading on Friday, reaching $6.51. 1,244,283 shares of the company traded hands, compared to its average volume of 1,335,269. The firm has a 50 day simple moving average of $7.48 and a 200-day simple moving average of $15.41. Arvinas, Inc. has a 52-week low of $5.90 and a 52-week high of $36.20. The stock has a market capitalization of $475.17 million, a PE ratio of -2.35 and a beta of 2.21.

Arvinas (NASDAQ:ARVN - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The company reported $1.14 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.93) by $2.07. Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. During the same quarter in the previous year, the company earned ($0.97) EPS. The business's revenue for the quarter was up 646.2% on a year-over-year basis. As a group, research analysts predict that Arvinas, Inc. will post -3.81 EPS for the current year.

Analysts Set New Price Targets

ARVN has been the subject of a number of recent analyst reports. Wedbush downgraded shares of Arvinas from an "outperform" rating to a "neutral" rating and cut their price target for the stock from $57.00 to $12.00 in a report on Wednesday, March 12th. BMO Capital Markets dropped their price objective on shares of Arvinas from $20.00 to $10.00 and set an "outperform" rating for the company in a research note on Monday, May 5th. HC Wainwright cut their price target on shares of Arvinas from $81.00 to $24.00 and set a "buy" rating on the stock in a report on Friday, May 2nd. Citigroup decreased their price objective on shares of Arvinas from $10.00 to $9.50 and set a "neutral" rating for the company in a research report on Monday, May 5th. Finally, Wells Fargo & Company decreased their price objective on shares of Arvinas from $26.00 to $19.00 and set an "overweight" rating for the company in a research report on Friday, May 2nd. Eight investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat, Arvinas currently has an average rating of "Moderate Buy" and a consensus target price of $20.92.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.